The New England Journal of Medicine

NOVEMBER 15, 2024

In patients with heart failure with preserved ejection fraction and obesity, treatment with tirzepatide led to a lower risk of death from cardiovascular causes or worsening heart-failure events than placebo.

Preserved Ejection Fraction 75

Preserved Ejection Fraction Heart Failure Obesity 75

HCPLive

AUGUST 1, 2024

Eli Lilly's tirzepatide showed a 38% reduction in heart failure outcomes and improved symptoms in adults with HFpEF and obesity in the phase 3 SUMMIT trial.

Heart Failure 69

Heart Failure Obesity Outcomes 69

Cardiovascular Diabetology

FEBRUARY 6, 2025

The rising prevalence of obesity and its association with heart failure with preserved ejection fraction (HFpEF) highlight an urgent need for a diagnostic approach tailored to this population. Diagnosing HFpEF.

Preserved Ejection Fraction 83

Preserved Ejection Fraction Heart Failure Obesity 83

Med Page Today

OCTOBER 2, 2024

(MedPage Today) -- The novel investigational weight loss agent HU6 had mixed results specifically targeting obesity-related heart failure with preserved ejection fraction (HFpEF), based on the small HuMain-HFpEF trial. After 19 weeks on daily.

Preserved Ejection Fraction 105

Preserved Ejection Fraction Obesity Heart Failure 105

Cardiovascular Diabetology

FEBRUARY 11, 2024

Heart failure (HF) is increasing at an alarming rate, primary due to the rising in aging, obesity and diabetes. Notably, individuals with type 1 diabetes (T1D) face a significantly elevated risk of HF, leading.

Heart Failure 111

Heart Failure Diabetes Obesity 111

Cardiovascular Diabetology

AUGUST 13, 2024

Heart failure with preserved ejection fraction (HFpEF) is associated with systemic inflammation, obesity, metabolic syndrome, and gut microbiome changes. Increased trimethylamine-N-oxide (TMAO) levels are pred.

Preserved Ejection Fraction 103

Preserved Ejection Fraction Heart Failure Obesity Research 103

American College of Cardiology

APRIL 6, 2024

The goal of the STEP-HFpEF DM trial was to compare the safety and efficacy of semaglutide among patients with obesity-related heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes mellitus (DM).

Preserved Ejection Fraction 69

Preserved Ejection Fraction Heart Failure Obesity Diabetes 69

JAMA Cardiology

MARCH 11, 2025

This randomized clinical trial evaluates if HU6, a controlled metabolic accelerator, reduces body weight, improves body composition, and increases exercise capacity in patients with obesity-related heart failure with preserved ejection fraction (HFpEF).

Preserved Ejection Fraction 71

Preserved Ejection Fraction Obesity Heart Failure Exercise 71

DAIC

JULY 31, 2024

mtaschetta-millane Wed, 07/31/2024 - 06:00 July 31, 2024 — A novel study co-authored by a heart failure cardiologist at University Hospitals Harrington Heart & Vascular Institute, demonstrates the effectiveness of a newly developed scoring system in identifying patients with Heart Failure with Preserved Ejection Fraction (HFpEF).

Heart Failure 111

Heart Failure Preserved Ejection Fraction Research Hospital 111

American College of Cardiology

MARCH 31, 2025

25 in Chicago and simultaneously published in JACC.

Preserved Ejection Fraction 64

Preserved Ejection Fraction Kidney Disease Obesity Heart Failure 64

HCPLive

NOVEMBER 19, 2024

Muthiah Vaduganathan, MD, MPH, discusses the need for cardiology to embrace a role for GLP-1 receptor agonists and incretin therapies, with a focus on obesity-related HFpEF.

Heart Failure 118

Heart Failure Obesity 118

CardiacWire

JANUARY 15, 2025

Bayers FINEARTS-HF study revealed that finerenone could be poised to become the next big heart failure treatment at ESC 2024, and a new series of JACC sub-studies just further strengthened its case. Finerenone (Bayers Kerendia) got its start with CKD, and is the first mineralocorticoid receptor antagonist to be used for HF.

Heart Failure 59

Heart Failure Obesity BMI 59

American College of Cardiology

NOVEMBER 16, 2024

In patients with obesity and heart failure with preserved ejection fraction (HFpEF), weekly treatment with tirzepatide over approximately two years reduced the risk of worsening heart failure events, based on findings from the SUMMIT trial.

Preserved Ejection Fraction 75

Preserved Ejection Fraction Quality of Life Obesity Heart Failure 75

JAMA Cardiology

NOVEMBER 15, 2024

In this case series study, pulmonary artery systolic, diastolic, and mean pressures of 2 participants with obesity and heart failure with preserved ejection fraction were measured at zero gravity during parabolic flight to assess the effect of external constraint on left ventricular filling pressures.

Preserved Ejection Fraction 73

Preserved Ejection Fraction Heart Failure Obesity Pulmonary 73

Frontiers in Cardiovascular Medicine

DECEMBER 13, 2023

Background The obesity occurrence has achieved epidemic levels worldwide and several studies indicate a paradoxical similarity among obesity and the prognosis in heart failure (HF). Conclusion In not hospitalized patients with HFREF of ischemic etiology, obesity was not a protective factor.

Outpatient 59

Outpatient Obesity Heart Failure BMI 59

American College of Cardiology

JANUARY 15, 2025

Alison Bailey and Milton Packer examine the power of tirzepatide expanding beyond weight loss and treating diabetes in addition to reducing heart failure events in patients with obesity-related HFpEF. In this interview, Drs.

Preserved Ejection Fraction 49

Preserved Ejection Fraction Heart Failure Obesity Diabetes 49

Circulation

JANUARY 27, 2025

METHODS:The AHA, through its Epidemiology and Prevention Statistics Committee, continuously monitors and evaluates sources of data on heart disease and stroke in the United States and globally to provide the most current information available in the annual Statistical Update with review of published literature through the year before writing.

Heart Disease 81

Heart Disease Peripheral Arterial Disease Stroke Strokes 81

American College of Cardiology

NOVEMBER 16, 2024

The goal of the SUMMIT trial was to compare the safety and efficacy of tirzepatide among patients with heart failure with preserved ejection fraction (HFpEF) and obesity.

Preserved Ejection Fraction 49

Preserved Ejection Fraction Heart Failure Obesity Article 49

American College of Cardiology

APRIL 10, 2024

What are the effects of semaglutide across a broad range of outcomes in people with obesity-related heart failure with preserved ejection fraction (HFpEF) with and without diabetes, and consistency across key patient subgroups?

Preserved Ejection Fraction 61

Preserved Ejection Fraction Obesity Heart Failure Diabetes 61

American College of Cardiology

DECEMBER 13, 2023

Obesity is quite common in patients suffering from heart failure with preserved ejection fraction (HFpEF). Semaglutide is a glucagon-like peptide-1 receptor agonist that has been shown to cause weight loss and reduce cardiovascular events in patients with obesity.

Preserved Ejection Fraction 64

Preserved Ejection Fraction Heart Failure Obesity Article 64

American College of Cardiology

JULY 16, 2024

For patients with obesity-related heart failure with preserved ejection fraction (HFpEF), what is the effect of semaglutide on change in New York Heart Association (NYHA) functional class over time?

Preserved Ejection Fraction 61

Preserved Ejection Fraction Obesity Heart Failure Article 61

American College of Cardiology

JANUARY 8, 2024

Obesity is a multifaceted disease that is directly and indirectly implicated in atherosclerotic cardiovascular disease (CVD), heart failure (HF), atrial fibrillation (AF), and multiple CVD risk factors, including dyslipidemia, hypertension, type 2 diabetes mellitus (DM), and sleep disorders.

Obesity 71

Obesity Atrial Fibrillation Heart Failure Risk Factors 71

Med Page Today

APRIL 7, 2024

(MedPage Today) -- ATLANTA -- Weight loss and heart failure benefits with semaglutide (Wegovy) extended to patients with obesity-related heart failure with preserved ejection fraction (HFpEF) who have type 2 diabetes, the STEP-HFpEF DM trial showed.

Preserved Ejection Fraction 96

Preserved Ejection Fraction Diabetes Heart Failure Obesity 96

American College of Cardiology

AUGUST 7, 2024

In this week’s View, Dr. Eagle looks at post-capillary pulmonary hypertension in heart failure and the revised European guideline definition. He then explores obesity in adolescents and its impact on our societal health.

Obesity 61

Obesity Pulmonary Hypertension TAVR 61

Cardiovascular Diabetology

FEBRUARY 16, 2025

Obesity is common in the heart failure (HF) population and is regarded as an important risk factor for developing HF. Greater skeletal muscle mass has shown to be the underlying protective factor against cardi.

Heart Failure 52

Heart Failure Obesity Risk Factors Diabetes 52

American College of Cardiology

AUGUST 26, 2024

The goal of the STEP-HFpEF trial was to compare the safety and efficacy of semaglutide among patients with heart failure with preserved ejection fraction (HFpEF) and obesity.

Preserved Ejection Fraction 58

Preserved Ejection Fraction Obesity Heart Failure Article 58

Becker's Hospital Review - Cardiology

NOVEMBER 18, 2024

The GLP-1 tirzepatide, the active ingredient in Eli Lilly's Mounjaro, was found to reduce the risk of heart failure by 46% among individuals with obesity, according to a study published Nov. 16 in The New England Journal of Medicine and presented at the American Heart Association's annual Scientific Sessions.

Heart Failure 59

Heart Failure Obesity 59

Cardiovascular Diabetology

SEPTEMBER 10, 2024

Although the “obesity paradox” is comprehensively elucidated in heart failure (HF) with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF), the role of body composition in left v.

Preserved Ejection Fraction 52

Preserved Ejection Fraction Heart Failure Obesity Outcomes 52

Science Daily - Heart Disease

JUNE 23, 2024

Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves symptoms in men and women with a common type of heart failure that has had few therapeutic options. Women experienced greater weight loss and the same symptom benefits compared with men.

Obesity 102

Obesity Heart Failure Diabetes 102

Open Heart

MAY 23, 2024

Pre-eclampsia and heart failure have common risk factors, including hypertension, obesity and diabetes. It is not known whether heart failure increases the risk of pre-eclampsia. This study examines whether pregestational heart failure increases the risk of pre-eclampsia.

Heart Disease 98

Heart Disease Heart Failure Risk Factors Obesity 98

American College of Cardiology

JUNE 24, 2024

Semaglutide reduces body weight to a greater extent in women with obesity-related heart failure with preserved ejection fraction (HFpEF) than in men, and improved Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) to the same extent in both women and men, according to results from a prespecified secondary analysis of pooled (..)

Preserved Ejection Fraction 66

Preserved Ejection Fraction Obesity Heart Failure Cardiomyopathy 66

Cardiovascular Diabetology

MARCH 21, 2025

Heart failure (HF) with preserved ejection fraction (HFpEF) is increasingly prevalent worldwide due to aging and comorbidities. Epicardial adipose tissue (EAT), favored by diabetes and obesity, was shown to co.

Preserved Ejection Fraction 52

Preserved Ejection Fraction Heart Failure Obesity Diabetes 52

Frontiers in Cardiovascular Medicine

JULY 17, 2024

Recently, indisputable evidence has shown that the TyG index is strongly associated with cardiovascular disease [CVD, including atherosclerosis, heart failure (HF), and hypertension] prognosis and mortality. Finally, we summarized the mechanism of the “obesity paradox.”

Heart Failure 64

Heart Failure Atherosclerosis Biomarkers Obesity 64

Becker's Hospital Review - Cardiology

NOVEMBER 7, 2024

Semaglutide treatment was found to reduce healthcare costs significantly for patients with overweight or obesity and who had either heart failure or atherosclerotic cardiovascular disease, according to studies presented Nov. 3-6 at the Obesity Society's annual Obesity Week conference and reviewed Nov.

Heart Failure 52

Heart Failure Obesity Cardiovascular Disease 52

Cardiovascular Diabetology

MARCH 25, 2025

Heart failure (HF) is increasingly recognized as a heterogeneous cardiometabolic disorder, often in the context of overweight/obesity independently from diabetes. Sodium-glucose cotransporter-2 inhibitors (SGL.

Heart Failure 52

Heart Failure Obesity Diabetes 52

HeartRhythm

APRIL 30, 2024

Catheter Ablation for Atrial Fibrillation (AFib) in heart failure is now a class I indication for patients with heart failure. Evidence supports the relationship between obesity and the incidence and recurrence of Afib.

Atrial Fibrillation 40

Atrial Fibrillation Heart Failure Obesity Ablation 40

European Journal of Heart Failure

DECEMBER 22, 2023

Abstract Background N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations are lower in patients with obesity. The interaction between body mass index (BMI) and NT-proBNP with respect to heart failure (HF) risk remains incompletely defined.

Heart Failure 75

Heart Failure BMI Obesity Article 75